|
64 Companies |
|
21 Products |
|
21 Products |
|
23 Mechanisms of Action |
|
221 Trials |
|
11162 News |
|
| «12...130131132133134135136137138139140141142» |
- Enrollment closed: MAPLE: Study of an Intervention to Improve Problem List Accuracy and Use (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=140, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Enrolling by invitation --> Active, not recruiting
- || Trial primary completion date: QUESST: Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=200, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Mar 2015 --> Jun 2015
- | bortezomib / Generic mfg.
Enrollment open: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) (clinicaltrials.gov) - Dec 19, 2014
P2, N=18, Recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Mar 2015 --> Jun 2015 Not yet recruiting --> Recruiting
- | New P2 trial: The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor (clinicaltrials.gov) - Dec 16, 2014
P2, N=240, Recruiting, Sponsor: Tang-Du Hospital
- Trial primary completion date: Therapeutic Plasma Exchange in MG (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=10, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Jun 2015
- | Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial initiation date: Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis (clinicaltrials.gov) - Dec 7, 2014
P2, N=25, Not yet recruiting, Sponsor: Mazen Dimachkie, MD
Trial primary completion date: Aug 2014 --> Jun 2015 Initiation date: Jun 2014 --> Jan 2015
- |||||||||| Soliris (eculizumab) / AstraZeneca
New P3 trial: Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - Nov 28, 2014
P3, N=92, Enrolling by invitation, Sponsor: Alexion Pharmaceuticals
- Enrollment open: MGEX: Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=44, Recruiting, Sponsor: Assistance Publique - H
Initiation date: Jun 2014 --> Jan 2015 Not yet recruiting --> Recruiting
- | bortezomib / Generic mfg.
Trial initiation date: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) (clinicaltrials.gov) - Oct 17, 2014
P2, N=18, Not yet recruiting, Sponsor: Charite University, Berlin, Germany
Not yet recruiting --> Recruiting Initiation date: May 2014 --> Nov 2014
- Ventolin (albuterol) / GSK
Phase classification: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Oct 17, 2014
P1, N=21, Completed, Sponsor: Mayo Clinic
Initiation date: May 2014 --> Nov 2014 Phase classification: P=N/A --> P1
- Benlysta (belimumab) / GSK
Trial primary completion date: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Oct 2, 2014
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
Phase classification: P=N/A --> P1 Trial primary completion date: Aug 2014 --> Aug 2015
- || Trial primary completion date: The Role of the Thymus in Myasthenia Gravis (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Dec 2013 --> Dec 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Sep 19, 2014
P2, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Jun 2014 --> Jun 2017
- | Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
Enrollment closed, Trial primary completion date: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Aug 6, 2014
P3, N=36, Active, not recruiting, Sponsor: Catalyst Pharmaceutical Partners, Inc
Trial primary completion date: Jun 2014 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Sep 2014
- Trial initiation date: MGEX: Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=44, Not yet recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Sep 2014 Initiation date: Feb 2014 --> Sep 2014
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma
Clinical: EAP-001: Expanded Access Study Amifampridine Phosphate in Congenital Myasthenic Syndrome (CMS) (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=0, Available, Sponsor: Catalyst Pharmaceutical Partners, Inc
- | Enrollment closed: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (clinicaltrials.gov) - Jul 4, 2014
P2, N=30, Active, not recruiting, Sponsor: Jacobus Pharmaceutical
Initiation date: Feb 2014 --> Sep 2014 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open: BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis (clinicaltrials.gov) - May 8, 2014
P2, N=50, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment closed: Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis (clinicaltrials.gov) - Apr 29, 2014
P1, N=10, Active, not recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Clinical: National Registry for Egyptian Pediatric Neuromuscular Diseases (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=200, Recruiting, Sponsor: Ain Shams University
- prednisone / Generic mfg., azathioprine / Generic mfg.
Enrollment closed: MYACOR: Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis (clinicaltrials.gov) - Apr 10, 2014
P4, N=114, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial: BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis (clinicaltrials.gov) - Apr 8, 2014
P2, N=50, Not yet recruiting, Sponsor: Yale University
- | Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
Enrollment change: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Apr 1, 2014
P3, N=36, Recruiting, Sponsor: Catalyst Pharmaceutical Partners, Inc
Recruiting --> Active, not recruiting N=30 --> 36
- bortezomib / Generic mfg.
New P2 trial: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) (clinicaltrials.gov) - Apr 1, 2014
P2, N=18, Not yet recruiting, Sponsor: Charite University, Berlin, Germany
- | Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
New P2 trial: Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis (clinicaltrials.gov) - Mar 30, 2014
P2, N=25, Not yet recruiting, Sponsor: Mazen Dimachkie, MD
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial: A Phase II Trial of Rituximab In Myasthenia Gravis (clinicaltrials.gov) - Mar 19, 2014
P2, N=50, Not yet recruiting, Sponsor: Yale University
- |||||| Soliris (eculizumab) / AstraZeneca
Enrollment open: Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) (clinicaltrials.gov) - Mar 4, 2014
P3, N=92, Recruiting, Sponsor: Alexion Pharmaceuticals
N=30 --> 36 Not yet recruiting --> Recruiting
- Ventolin (albuterol) / GSK
Enrollment change: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Jan 7, 2014
P=N/A, N=21, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting N=50 --> 21
- | Ventolin (albuterol) / GSK
Trial completion: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Jan 7, 2014
P=N/A, N=21, Completed, Sponsor: Mayo Clinic
N=50 --> 21 Recruiting --> Completed
- ||||| tacrolimus oral / Generic mfg.
Enrollment closed: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis (clinicaltrials.gov) - Dec 9, 2013
P3, N=83, Active, not recruiting, Sponsor: Astellas Pharma Inc
Recruiting --> Completed Completed --> Active, not recruiting
- |||||||||| Soliris (eculizumab) / AstraZeneca
New P3 trial: Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) (clinicaltrials.gov) - Nov 26, 2013
P3, N=92, Recruiting, Sponsor: Alexion Pharmaceuticals
- prednisone / Generic mfg.
Enrollment change: EPITOME: Efficacy of Prednisone In the Treatment of Ocular Myasthenia (clinicaltrials.gov) - Nov 6, 2013
P3, N=11, Terminated, Sponsor: Michael Benatar
Completed --> Active, not recruiting N=88 --> 11
- prednisone / Generic mfg.
Trial termination: EPITOME: Efficacy of Prednisone In the Treatment of Ocular Myasthenia (clinicaltrials.gov) - Oct 30, 2013
P3, N=11, Terminated, Sponsor: Michael Benatar
N=88 --> 11 Active, not recruiting --> Terminated; Slow recruitment rate
- Clinical: Therapeutic Plasma Exchange in MG (clinicaltrials.gov) - Aug 21, 2013
P=N/A, N=10, Recruiting, Sponsor: Duke University
- Enrollment change: CoRDS: Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (clinicaltrials.gov) - Aug 12, 2013
P=N/A, N=10000, Recruiting, Sponsor: Sanford Health
Active, not recruiting --> Terminated; Slow recruitment rate N=1000 --> 10000
- | Benlysta (belimumab) / GSK
Enrollment open: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - May 8, 2013
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
N=1000 --> 10000 Not yet recruiting --> Recruiting
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Clinical: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Apr 8, 2013
P=N/A, N=10, Recruiting, Sponsor: St. Louis University
- New P3 trial: Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome (clinicaltrials.gov) - Apr 3, 2013
P3, N=0, Available, Sponsor: University of Colorado, Denver
- Clinical: CoRDS: Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=10000, Recruiting, Sponsor: Sanford Health
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: A Pilot Trial of Rituxan in Refractory Myasthenia Gravis (clinicaltrials.gov) - Jan 14, 2013
P1/2, N=10, Completed, Sponsor: University of Vermont
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: FORCE: Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis (clinicaltrials.gov) - Dec 9, 2012
P2, N=30, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Recruiting --> Completed
- | prednisone / Generic mfg.
Enrollment closed: Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (clinicaltrials.gov) - Dec 3, 2012
P3, N=150, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: Efficacy of Methotrexate in Myasthenia Gravis (clinicaltrials.gov) - Nov 20, 2012
P2, N=50, Active, not recruiting, Sponsor: University of Kansas
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || leflunomide / Generic mfg., azathioprine / Generic mfg.
New P3 trial: The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy (clinicaltrials.gov) - Nov 13, 2012
P3, N=158, Recruiting, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
- tirasemtiv (CK-2017357) / Astellas, Cytokinetics
Trial termination: Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - Oct 29, 2012
P2, N=32, Terminated, Sponsor: Cytokinetics
Recruiting --> Active, not recruiting Recruiting --> Terminated; Closed after complete treatment of 32 patients after 21 months' recruitment.
- | Benlysta (belimumab) / GSK
Enrollment change: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Sep 12, 2012
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Terminated; Closed after complete treatment of 32 patients after 21 months' recruitment. N=120 --> 42
- Enrollment change: Training for Diagnosing Neurological Disorders (clinicaltrials.gov) - Jul 13, 2012
P=N/A, N=400, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=120 --> 42 N=200 --> 400
- | New P2 trial: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (clinicaltrials.gov) - Jan 17, 2012
P2, N=30, Recruiting, Sponsor: Jacobus Pharmaceutical
- prednisone / Generic mfg.
Trial initiation date: EPITOME: Efficacy of Prednisone In the Treatment of Ocular Myasthenia (clinicaltrials.gov) - Dec 28, 2011
P3, N=11, Terminated, Sponsor: Michael Benatar
N=200 --> 400 Initiation date: May 2011 --> Dec 2011
- Enrollment closed: The Role of the Thymus in Myasthenia Gravis (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=80, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Initiation date: May 2011 --> Dec 2011 Recruiting --> Active, not recruiting